Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule

Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now. On February 11, Royalty Pharma reported a year of robust financial performance in 2025, marked by a 16% increase in total portfolio receipts and an 18% jump in Q4 alone. The company achieved a notable 15.8% return on invested capital and successfully met its five-year $10 billion to $12 billion capital deployment target a full year ahead of schedule.

Strategically, the company completed $4.7 billion in transactions focused on attractive therapies and received a boost from several positive clinical and regulatory milestones, including the FDA approval of Myqorzo. Management highlighted the growing importance of synthetic royalties, which the company views as an increasingly popular alternative to traditional debt or equity financing for biotech firms.

Despite this momentum, the company is preparing for some headwinds in 2026, including the loss of exclusivity for Promacta and the introduction of a biosimilar for Tysabri in the US market. In 2026, Royalty Pharma expects portfolio receipts to range between $3.275 and $3.425 billion, representing a modest growth forecast of 3% to 8%.

Royalty Pharma (NASDAQ:RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the US.

While we acknowledge the potential of RPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.